Monalizumab Biosimilar (NKG2A / CD94 Reference Antibody)
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A) . Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
Product Specifications
Target
Monalizumab Biosimilar (Anti-NKG2A / CD94 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LV710281 1.0 µg DNA
FTSJ3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
Sign In for Pricing
View Details GTR15174685 1 Vial
Lentiviral mouse Mcm3 shRNA (UAS) - Lentiviral mouse Mcm3 shRNA (UAS, RFP) plasmid
Sign In for Pricing
View Details